Literature DB >> 27749947

Unfinished Business in Preventing Alzheimer Disease.

Jason Karlawish1, Kenneth M Langa2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27749947      PMCID: PMC5458728          DOI: 10.1001/jamainternmed.2016.6310

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  7 in total

1.  Measuring the Value of Prescription Drugs.

Authors:  Peter J Neumann; Joshua T Cohen
Journal:  N Engl J Med       Date:  2015-11-18       Impact factor: 91.245

2.  Regulatory innovation and drug development for early-stage Alzheimer's disease.

Authors:  Nicholas Kozauer; Russell Katz
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

3.  Researchers test strategies to prevent Alzheimer disease.

Authors:  M J Friedrich
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

4.  Functional deficits in patients with mild cognitive impairment: prediction of AD.

Authors:  M H Tabert; S M Albert; L Borukhova-Milov; Y Camacho; G Pelton; X Liu; Y Stern; D P Devanand
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

5.  Monetary costs of dementia in the United States.

Authors:  Michael D Hurd; Paco Martorell; Adeline Delavande; Kathleen J Mullen; Kenneth M Langa
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

Review 6.  Decision analytic models for Alzheimer's disease: state of the art and future directions.

Authors:  Joshua T Cohen; Peter J Neumann
Journal:  Alzheimers Dement       Date:  2008-05       Impact factor: 21.566

7.  Modeling test and treatment strategies for presymptomatic Alzheimer disease.

Authors:  James F Burke; Kenneth M Langa; Rodney A Hayward; Roger L Albin
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

  7 in total
  3 in total

Review 1.  Measuring cognition and function in the preclinical stage of Alzheimer's disease.

Authors:  Sandra Weintraub; Maria C Carrillo; Sarah Tomaszewski Farias; Terry E Goldberg; James A Hendrix; Judith Jaeger; David S Knopman; Jessica B Langbaum; Denise C Park; Michael T Ropacki; Sietske A M Sikkes; Kathleen A Welsh-Bohmer; Lisa J Bain; Robert Brashear; Kumar Budur; Ana Graf; Ferenc Martenyi; Marta Segardahl Storck; Christopher Randolph
Journal:  Alzheimers Dement (N Y)       Date:  2018-02-13

2.  Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

Authors:  Emily A Largent; Jason Karlawish; Joshua D Grill
Journal:  Alzheimers Res Ther       Date:  2018-09-27       Impact factor: 6.982

Review 3.  Study partners should be required in preclinical Alzheimer's disease trials.

Authors:  Joshua D Grill; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2017-12-06       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.